All In Biotech

Drug Trial Radar · NCT02605954

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects

Last checked: Nov 20, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Nov 18, 2015

Primary completion

Jun 14, 2017

Study completion Jan 24, 2018

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.

Conditions

  • HIV-1 Infection

Interventions

  • E/C/F/TAFDrug

    150/150/200/10 mg FDC tablets administered orally once daily

  • ABC/3TCDrug

    600/300 mg tablets administered orally once daily

  • Third Antiretroviral AgentDrug

    Third antiretroviral agents could include one of the following: * ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC * DRV+COBI or DRV/COBI FDC * darunavir (DRV; Prezista®) + RTV * lopinavir/ritonavir (LPV/r; Kaletra®) * atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®) * efavirenz (EFV; Sustiva®) * etravirine (ETR; Intelence®) * nevirapine (NVP; Viramune®) * rilpivirine (RPV; Edurant®) * dolutegravir (DTG; Tivicay®) * raltegravir (RAL; Isentress®) * fosamprenavir (FPV; Lexiva®) + RTV * saquinavir (SQV; Invirase®) + RTV * ATV (no booster) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24Time frame: Week 24

Locations

49 sites in 6 countries. Site status is shown where the registry gives one.

  • Spectrum Medical Group

    Phoenix, Arizona

  • Ruane Clinical Research Group

    Los Angeles, California

  • Capital Medical Associates, P.C.

    Washington D.C., District of Columbia

  • Georgetown University

    Washington D.C., District of Columbia

  • Gary Richmond, MD, PA, Inc.

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • Steinhart Medical Associates dba The Kinder Medical Group

    Miami, Florida

  • Triple O Research Institute PA

    West Palm Beach, Florida

  • The Positive Health Clinic, Allegheny Health Network

    Pittsburgh, Pennsylvania

  • Central Texas Clinical Research

    Austin, Texas

  • AIDS Arms, Inc./Trinity Health & Wellness Center

    Dallas, Texas

  • Tarrant County ID Associates

    Fort Worth, Texas

  • CHU - Groupe Saint-Andre

    Bordeaux, France

  • Hopital Henri Mondor

    Créteil, France

  • Hopital Europeen Marseille

    Marseille, France

  • C.H.U. de Nantes

    Nantes, France

  • C.H.U. de NICE

    Nice, France

  • CHU Hotel Dieu

    Paris, France

  • Hopital Lariboisiere

    Paris, France

  • Hopital Necker les Enfants Malades

    Paris, France

  • Hopital Saint Antoine

    Paris, France

  • Hopital Saint Louis

    Paris, France

  • Centre Hospitalier Gustave Dron

    Tourcoing, France

  • Epimed GmbH

    Berlin, Germany

  • Universitatsklinikum Essen

    Essen, Germany

  • ICH Study Center Hamburg

    Hamburg, Germany

  • Universitatsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • ARNAS Garibaldi - Nesima

    Catania, Italy

  • Unit Infectious Diseases - University of Catania - ARNAS Garibaldi

    Catania, Italy

  • Azienda Ospedaliera Luigi Sacco

    Milan, Italy

  • Azienda Ospedaliero Universitaria Policlinico di Modena

    Modena, Italy

  • Azienda Ospedale San Paolo

    Monza, Italy

  • Azienda Ospedaliera San Gerardo

    Monza, Italy

  • Ospedale Civile S. Spirito AUSL

    Pescara, Italy

  • Unità Operativa Complessa di Malattie Infettive

    Pescara, Italy

  • Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.

    Roma, Italy

  • Comprensorio Ospedaliero Amedeo di Savoia

    Torino, Italy

  • Dipartimento di Malattie Infettive e Tropicali

    Torino, Italy

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.